2. Search Result
Search Result
Results for "

HepG2 xenografts

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

1

Fluorescent Dyes

4

Peptides

2

Inhibitory Antibodies

3

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-178018
    D574-0246

    iOXCT1

    		 Mitochondrial Metabolism Cancer
    D574-0246 is a dual-activity inhibitor of OXCT1, inhibiting both the ketolytic and succinyltransferase activities of OXCT1. D574-0246 reduces substrate-specific (LACTB K284) and global protein succinylation and decreases OXCT1 ketolytic activity in HepG2 cells. D574-0246 inhibits the viability of HCC cells (IC50: 16.49 μM in PLC cells, 6.656 μM in HepG2 cells). D574-0246 exerts anti-tumor efficacy in nude mice bearing OXCT1-overexpressing HepG2 xenograft tumors. D574-0246 can be used for the study of hepatocellular carcinoma (HCC) .
    D574-0246
  • HY-116522
    AR420626
    4 Publications Verification

    		 Free Fatty Acid Receptor Histone Methyltransferase HDAC mTOR CaMK p38 MAPK Epigenetic Reader Domain GLUT nAChR TNF Receptor Metabolic Disease Inflammation/Immunology Cancer
    AR420626 is a selective agonist of free fatty acid receptor 3 (FFAR3) (IC50=117 nM). AR420626 has anti-inflammatory, anticancer and antidiabetic activities. AR420626 improves neurogenic diarrhea by inhibiting nAChR mediated neural pathways. AR420626 inhibits the growth of HepG2 xenografts and inhibits the proliferation of hepatoma cells by inducing apoptosis. AR420626 also suppresses allergic asthma and eczema and has the ability to activate GPR41 to increase Ca 2+ signal-mediated glucose uptake and improve diabetes .
    AR420626
  • HY-N2217
    Rotundic acid

    		Akt mTOR p38 MAPK Apoptosis Phosphatase Interleukin Related NF-κB PI3K Keap1-Nrf2 Heme Oxygenase (HO) Toll-like Receptor (TLR) Reactive Oxygen Species (ROS) Metabolic Disease Inflammation/Immunology Cancer
    Rotundic acid is an orally effective triterpenoid with a Kd value of 51.3 µM for PTP1B. Rotundic acid downregulates the AKT/mTOR pro-survival pathway and modulates the MAPK pathway. Rotundic acid induces cell cycle S-phase arrest, DNA damage and apoptosis; it inhibits migration, invasion, angiogenesis and proliferation of cancer cells. Rotundic acid improves leptin sensitivity, regulates gut microbiota and reduces cellular senescence. Rotundic acid can be used in research related to hepatocellular carcinoma, obesity, aging, acute lung injury and type 2 diabetes .
    Rotundic acid
  • HY-150538
    STAT3-IN-12
    1 Publications Verification

    		 STAT Apoptosis Cancer
    STAT3-IN-12 is a potent STAT3 signal inhibitor that can inhibit IL-6 induced JAK/STAT3 signalling pathway activation. STAT3-IN-12 inhibits cancer cell growth, migration, and induce cell apoptosis as well as cycle arrest. STAT3-IN-12 can be used in cancer-related research, such as hepatocellular carcinoma (HCC) and oesophageal carcinoma .
    STAT3-IN-12
  • HY-175208
    MST3-IN-1

    		Hippo (MST) Caspase Bcl-2 Family Apoptosis Cancer
    MST3-IN-1 is a selective and orally active MST3 inhibitor, with an IC50 of 122.4 nM. MST3-IN-1 shows antiproliferative activity against HepG2 cell. MST3-IN-1 effectively induces apoptosis in HepG2 cells, and halts the cell cycle at the G2/M transition. MST3-IN-1 significantly suppressed tumor growth in HepG2 xenograft mice. MST3-IN-1 can be used for the study of liver cancer .
    MST3-IN-1
  • HY-204056
    Telomerase-IN-8

    		Telomerase Cancer
    Telomerase-IN-8 is an orally active telomerase inhibitor, with an IC50 value of 0.98 μM. Telomerase-IN-8 exhibits potent antiproliferative activity against multiple tumor cell lines, including PC3, Bcap-37, MGC-803 and HepG2. Telomerase-IN-8 demonstrates potent antitumor efficacy in S180 sarcoma or HepG2 hepatoma xenograft mice. Telomerase-IN-8 can be used for the study of telomerase-targeted anticancer .
    Telomerase-IN-8
  • HY-170027
    LW1564

    		HIF/HIF Prolyl-Hydroxylase AMPK Cancer
    LW1564 is an inhibitor for HIF-1α with an IC50 of 1.2 µM in HepG2. LW1564 inhibits mitochondrial respiration, reduces ATP production, stimulates HIF-1α degradation, and inhibits proliferation of various cancer cells with GI50 of 0.4-4.6 μM. LW1564 activates AMPK signaling pathway and inhibits lipid synthesis. LW1564 exhibits antitumor in HepG2 xenograft mouse model .
    LW1564
  • HY-175208A
    MST3-IN-1 TFA

    		Hippo (MST) Caspase Bcl-2 Family Apoptosis Cancer
    MST3-IN-1 TFA (Compound LD-1) is a selective and orally active MST3 inhibitor, with an IC50 of 122.4 nM. MST3-IN-1 TFA shows antiproliferative activity against HepG2 cell. MST3-IN-1 TFA effectively induces Apoptosis in HepG2 cells, and halts the cell cycle at the G2/M transition. MST3-IN-1 TFA significantly suppressed tumor growth in HepG2 xenograft mice. MST3-IN-1 TFA can be used for the study of liver cancer .
    MST3-IN-1 TFA
  • HY-176288
    eIF4E/eIF4G PPI-IN-1

    		Eukaryotic Initiation Factor (eIF) Bcl-2 Family Apoptosis Ras PERK Cancer
    eIF4E/eIF4G PPI-IN-1 is an eIF4E/eIF4G interaction inhibitor with a KD of 20.2 μM for eIF4E protein. eIF4E/eIF4G PPI-IN-1 plays an antitumor role in multiple modes of action including regulating the activity of eIF4E by inhibiting the Ras/MAPK/eIF4E signaling pathway, apoptosis and cell migration. eIF4E/eIF4G PPI-IN-1 suppresses the growth of HepG2 xenografts in nude mice and was relatively nontoxic to mice .
    eIF4E/eIF4G PPI-IN-1
  • HY-175176
    HDAC1/6-IN-3

    		HDAC Apoptosis Pyroptosis Reactive Oxygen Species (ROS) Caspase Cancer
    HDAC1/6-IN-3 is a potent HDAC inhibitor. HDAC1/6-IN-3 shows excellent inhibitory activities against HDAC1 (IC50 = 1.1 nM) and HDAC6 (IC50 = 2.7 nM). HDAC1/6-IN-3 significantly arrests HepG2 cells at the G0/G1 phase and induces apoptosis and pyroptosis. HDAC1/6-IN-3 exhibits significant antitumor activity in the HepG2 xenograft mode. HDAC1/6-IN-3 can be used for the study of cancers such as liver cancer, lung cancer, colon cancer and breast cancer .
    HDAC1/6-IN-3
  • HY-P991448
    MDX-1414

    		Glycoprotein VI Cancer
    MDX-1414 is a human IgG1 monoclonal antibody (mAb) targeting GPC3. MDX-1414 has antitumor activity in the HepG2 xenograft model. MDX-1414 can be used in liver cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    MDX-1414
  • HY-176740
    PROTAC Bcl-xL degrader-4

    		PROTACs Bcl-2 Family p38 MAPK Reactive Oxygen Species (ROS) Mitochondrial Metabolism Apoptosis ERK JNK Cancer
    PROTAC Bcl-xL degrader-4 (Compound 2-38-III) is a Bcl-xL PROTAC degrader. PROTAC Bcl-xL degrader-4 has strong anti-tumor activity against HepG2 cells and HUVEC cells. PROTAC Bcl-xL degrader-4 induces cells apoptosis by decreasing mitochondrial membrane potential and activating the MAPK signaling pathway. PROTAC Bcl-xL degrader-4 significantly inhibits tumor growth in xenograft tumor mouse models . Pink: MAPK ligand (HY-176741); Blue: CRBN ligase ligand (HY-10984); Black: linker (HY-W017440)
    PROTAC Bcl-xL degrader-4
  • HY-P10994
    Eps8 peptide 327

    Eps8(327-335)

    		 EGFR IFNAR Interleukin Related TNF Receptor Complement System Apoptosis Inflammation/Immunology Cancer
    Eps8 peptide 327 is an HLA-A*2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models .
    Eps8 peptide 327
  • HY-146465
    Anticancer agent 60

    		Microtubule/Tubulin Cancer
    Anticancer agent 60 (compound 3h) has antiproliferative activity against human HepG2 cells (IC50 = 4.13 μM) and presents antitumor efficacy in a human HepG2 xenograft mouse model .
    Anticancer agent 60
  • HY-178960
    Tubulin-IN-59

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin-IN-59 (Compound 8g) is an orally active Tubulin inhibitor. Tubulin-IN-59 exhibits potent anti-proliferative activity against HCT116 colorectal cancer, HeLa cervical cancer, and HepG2 liver cancer cell lines, with its IC₅₀ value ranging from 16 to 35 nM. Tubulin-IN-59 arrests HeLa cells in the G2/M phase and induces cell apoptosis. Tubulin-IN-59 demonstrates significant anti-tumor activity in the HT29 human colon cancer mouse xenograft model. Tubulin-IN-59 can be used for the study of colorectal cancer and cervical cancer .
    Tubulin-IN-59
  • HY-177268
    CHNQD-01426

    		Apoptosis Reactive Oxygen Species (ROS) PARP Caspase Akt Cancer
    CHNQD-01426 (Compound 4a) is an anticancer agent. CHNQD-01426 has cytotoxic activities against cancer cells. CHNQD-01426 significantly inhibits hepatocellular carcinoma cells proliferation via arresting S and G2/M phase cell cycle and induces apoptosis by inducing ROS production and elevating apoptosis-related proteins expression. CHNQD-01426 potently inhibits tumor growth in HepG2 xenograft mice model .
    CHNQD-01426
  • HY-163983
    Tubulin polymerization-IN-68

    		Microtubule/Tubulin Apoptosis PARP Caspase Cancer
    Tubulin polymerization-IN-68 (compound 32) is a tubulin inhibitor that can inhibit tubulin polymerization and destroy the cellular microtubule network. Tubulin polymerization-IN-68 can upregulate the expression of PARP-1 and caspase-3 and induce cell apoptosis, and has anticancer activity. Tubulin polymerization-IN-68 can effectively inhibit HepG2 (IC50=93 nM) and significantly inhibit the growth of HepG2 xenograft tumors in nude mice by oral administration .
    Tubulin polymerization-IN-68
  • HY-W276819
    PLK1-IN-9

    		Polo-like Kinase (PLK) Cancer
    PLK1-IN-9 (Compound M2) is an inhibitor for polo-like kinase 1 (PLK1), that inhibits PLK proteins modified with peptides 1010pT, cdc25c and PBIP, with IC50s of 1.6, 0.8 and 1.4 μM, respectively. PLK1-IN-9 inhibits proliferations of cancer cells HeLa, HL60, SNU387/499, HepG2, exhibits cytotoxicity and induces apoptosis. PLK1-IN-9 inhibits tumor growth in HepG2 xenograft mouse model .
    PLK1-IN-9
  • HY-130559
    SL-3-19

    		Microtubule/Tubulin Apoptosis Cancer
    SL-3-19 is a tubulin ligand. SL-3-19 exhibits antitumor activity against esophageal squamous cell carcinoma (ESCC) both in vitro and in vivo by inhibiting microtubule assembly, inducing G2/M phase cell cycle arrest and apoptosis, and disrupting tumor blood vessels. SL-3-19 has a higher activity than SL-1-73 (HY-130558). SL-3-19 can be used for the research of ESCC and other tumors .
    SL-3-19
  • HY-146114
    Antitumor agent-67

    		Microtubule/Tubulin Quinone Reductase Cancer
    Antitumor agent-67 (compound 3) is a potent antitumor agent. Antitumor agent-67 has highly selective toxicity to cancer cells and lower damage to normal cells. Antitumor agent-67 can be activated by NQO1 and effectively liberate podophyllotoxin and kill tumor cells. Antitumor agent-67 significantly suppresses cancer growth in HepG2 xenograft models without obvious toxicity .
    Antitumor agent-67
  • HY-163711
    trans-[Ru(2TU)(PPh3)2(bipy)]PF6

    		Biochemical Assay Reagents Cancer
    trans-[Ru(2TU)(PPh3)2(bipy)]PF6 (compound 1) is a an-ticancer agent and can be used for study of cancer .
    trans-[Ru(2TU)(PPh3)2(bipy)]PF6
  • HY-170565
    CHD-1

    		Mitophagy Apoptosis Cancer
    CHD-1 is a a hypoxia-activated antitumor prodrug. CHD-1 impairs mitochondrial morphology and membrane potential in hypoxic tumor cells, further triggering excessive mitophagy and inducing apoptosis. CHD-1 inhibits the growth of hypoxic tumor cells in vitro and the growth of HeLa xenograft in vivo .
    CHD-1
  • HY-P11618
    10P3Me

    		Glycoprotein VI Cancer
    10P3Me is a Glypican-3 (GPC3)-targeting probe with a Ka of 93.8 nM for the human target. 10P3Me exhibits high binding affinity to GPC3, targets GPC3-positive cells, and serves as an agent for PET imaging. 10P3Me selectively accumulates in GPC3-positive tumor tissues, including subcutaneous xenograft models and orthotopic HepG2-LUC liver cancer models, to achieve precise localization of lesions .
    10P3Me
  • HY-146040
    Anticancer agent 47

    		Apoptosis Cancer
    Anticancer agent 47 (compound 4j) is a potent anticancer agent. Anticancer agent 47 shows antiproliferative activities. Anticancer agent 47 induces apoptosis and cell cycle arrest at G0/G1 phase. Anticancer agent 47 shows shows antitumor activities in vivo .
    Anticancer agent 47
  • HY-172891
    CDK9/HDAC1/HDAC3-IN-1

    		CDK HDAC Apoptosis Cancer
    CDK9/HDAC1/HDAC3-IN-1 is dual-functional inhibitor of CDK9 and HDAC. CDK9/HDAC1/HDAC3-IN-1 inhibits the protein activity of CDK9/HDAC/HDAC3 with IC50 s of 0.17  μM, 1.73  μM and 1.11 μM for CDK9, HDAC1, and HDAC3, respectively. CDK9/HDAC1/HDAC3-IN-1 inhibits cancer cells by inducing cell apoptosis and cell cycle arrest in the G2/M phase, as well as tumor growth in a murine TNBC MDA-MB-231 xenograft model. CDK9/HDAC1/HDAC3-IN-1 has a broad-spectrum anti-cancer activity, such as breast cancer, cervical cancer, and liver cancer .
    CDK9/HDAC1/HDAC3-IN-1
  • HY-N10447
    Kurzipene D

    		Apoptosis Cancer
    Kurzipene D (compound 4) is a potent anticancer agent. Kurzipene D induces the apoptosis and arrested the HepG2 cell cycle at S stage. Kurzipene D shows anti-tumor effects using in vivo zebrafish model. Kurzipene D has the property of inhibiting tumor proliferation and migration .
    Kurzipene D
  • HY-P10995
    TAT-327

    		EGFR IFNAR Interleukin Related TNF Receptor Complement System Apoptosis Inflammation/Immunology Cancer
    TAT-327 is cell-penetrating peptide. TAT-327 selectively inserts into cancer cell membranes and shows potent antitumor activity. TAT-327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. TAT-327 significantly inhibits tumor growth in HT-29 xenograft mcie models .
    TAT-327
  • HY-180117
    MMP-2/9-IN-2

    		MMP STAT Apoptosis Cancer
    MMP-2/9-IN-2 (Compound 6k) is a MMP-2 and MMP-9 inhibitor, with IC50 values of 29.27 and 24.87 μM respectively. MMP-2/9-IN-2 exhibits good selective toxicity against multiple human hepatoma cell lines. MMP-2/9-IN-2 induces cell cycle arrest and apoptosis, significantly inhibits cell migration and invasion. MMP-2/9-IN-2 inhibits the phosphorylation of the STAT3 signaling pathway. MMP-2/9-IN-2 shows strong anti-tumor activity in a nude mouse xenograft model of HepG2 liver cancer cells .
    MMP-2/9-IN-2
  • HY-176908
    SIOC-XJC-SF02

    		Drug Derivative Apoptosis Cancer
    SIOC-XJC-SF02 is a Fenofibrate (HY-17356) derivative. SIOC-XJC-SF02 induces Apoptosis. SIOC-XJC-SF02 exhibits significant anti-cancer activity against hepatocellular carcinoma .
    SIOC-XJC-SF02
  • HY-P11624
    PP-60

    		Apoptosis Cancer
    PP-60 is an apoptosis inducer. PP-60 inhibits the proliferation of cancer cells and induces cancer cell apoptosis. PP-60 exerts anti-tumor effects in nude mouse liver tumor models. PP-60 is applicable to research related to cancers such as liver cancer, lung cancer, and prostate cancer .
    PP-60
  • HY-183078
    P6620

    		Deubiquitinase Cancer
    P6620 is an orally active USP7 inhibitor. P6620 specifically binds to USP7 and disrupts its interaction with LRRC41. P6620 exhibits anticancer activity against hepatocellular carcinoma. P6620 enhances the antitumor effect of Lenvatinib (HY-10981) in xenograft mouse models. P6620 can be used for the research of hepatocellular carcinoma .
    P6620
  • HY-130558
    SL-1-73

    		Apoptosis Microtubule/Tubulin Cancer
    SL-1-73 is a tubulin ligand. SL-1-73 exhibits antitumor activity against esophageal squamous cell carcinoma (ESCC) both in vitro and in vivo by inhibiting microtubule assembly, inducing G2/M phase cell cycle arrest and apoptosis, and disrupting tumor blood vessels. SL-1-73 can be used for the research of ESCC and other tumors .
    SL-1-73
  • HY-P992457
    SAR444200

    		Glycoprotein VI Interleukin Related Cancer
    SAR444200 is a nanobody T-cell engager targeting GPC3 (glypican-3) and TCRαβ (T-cell receptor αβ). SAR444200 has a KD of 0.023 nM for human GPC3 and a KD of 5.2 nM for human TCRαβ. SAR444200 mediates T-cell-dependent cytotoxicity, with high selectivity and killing activity against GPC3-positive tumor cells. SAR444200 binds to GPC3 in a dual-epitope manner, and binds to TCRαβ via its N-terminal nanobody, forming an artificial immunological synapse between T cells and tumor cells. SAR444200 can be used for the research of GPC3 + solid tumors, including liver cancer, lung squamous cell carcinoma and melanoma .
    SAR444200
  • HY-181823
    HOXA1-IN-1

    		HOXA TGF-beta/Smad Apoptosis Cancer
    HOXA1-IN-1 is a HOXA1 inhibitor. HOXA1-IN-1 downregulates HOXA1 protein levels, suppresses its transcriptional activity, and alters the expression of its downstream target genes. HOXA1-IN-1 induces DNA damage and apoptosis in cancer cells. HOXA1-IN-1 exhibits antitumor efficacy in xenograft models of colorectal cancer and triple-negative breast cancer. HOXA1-IN-1 shows synergistic activity in combination with Cisplatin (HY-17394). HOXA1-IN-1 can be used for the research of colorectal cancer and triple-negative breast cancer .
    HOXA1-IN-1
  • HY-182008
    NEURL1B-IN-1

    		Molecular Glues E1/E2/E3 Enzyme Apoptosis Notch PARP Caspase Bcl-2 Family Ligands for E3 Ligase Cancer
    NEURL1B-IN-1 is a molecular glue-like NEURL1B degrader with a Kd value of 46.2 nM. NEURL1B-IN-1 binds to Arg422 within the NHR2 domain of NEURL1B, triggers its autoubiquitination and proteasomal degradation, disrupts its interaction with DLL1, and attenuates the Notch signaling pathway. NEURL1B-IN-1 induces cell cycle arrest and apoptosis, and inhibits migration of hepatocellular carcinoma cells. NEURL1B-IN-1 is applicable to research related to hepatocellular carcinoma .
    NEURL1B-IN-1
  • HY-182048
    PD-1/PD-L1-IN-62

    		PD-1/PD-L1 mTOR Cancer
    PD-1/PD-L1-IN-62 is a PD-L1 inhibitor and mTOR modulator. PD-1/PD-L1-IN-62 inhibits PD-L1 with an IC50 of 6.9 nM and abrogates immune suppression mediated by the PD-1/PD-L1 pathway. By inhibiting mTOR phosphorylation and downregulating the downstream target SREBP1, PD-1/PD-L1-IN-62 significantly reduces cholesterol and triglyceride levels to decrease lipid accumulation. PD-1/PD-L1-IN-62 promotes the infiltration of CD3 +CD8 + T cells into tumor tissues, thereby effectively inhibiting tumor growth. PD-1/PD-L1-IN-62 can be used for the research of hepatocellular carcinoma .
    PD-1/PD-L1-IN-62
  • HY-D3167
    HDAC-IN-101

    		Fluorescent Dye HDAC Cancer
    HDAC-IN-101 (compound H6M) is a HDAC1 inhibitor and NTR/pH-activated fluorescent inducer, with an IC50 of 65 nM against human HDAC1. HDAC-IN-101 blocks cancer cell proliferation by inhibiting HDAC1. HDAC-IN-101 is reduced by overexpressed nitroreductase to generate H6AQ, a product that emits fluorescence under low pH conditions. HDAC-IN-101 is applicable for cancer-related research .
    HDAC-IN-101
  • HY-183790
    SMU-G4

    		Microtubule/Tubulin Apoptosis Caspase Cancer
    SMU-G4 is a Tubulin polymerization inhibitor. SMU-G4 induces G2/M phase cell cycle arrest, triggers Apoptosis, and upregulates the expression of Cleaved-Caspase 3. SMU-G4 exhibits in vivo anti-tumor activity in melanoma xenograft models. SMU-G4 can be used for research related to melanoma .
    SMU-G4
  • HY-N17442
    Echinoside A

    		Topoisomerase Caspase PARP Fungal DNA/RNA Synthesis Infection Cancer
    Echinoside A is a saponin. Echinoside A can be isolated from sea cucumber. Echinoside A inhibits the catalytic activity of Top2α, reduces the noncovalent binding of Top2α to DNA. Echinoside A activates Caspase-3 and induces PARP cleavage. Echinoside A induces Apoptosis. Echinoside A has anticancer activity against prostate cancer, hepatocellular carcinoma, and S-180 sarcoma. Echinoside A exhibits antifungal activity against a variety of fungi, with a minimum growth inhibitory concentration range of 3.12 to 50.0 μg/mL, including potent activity against Aspergillus and Penicillium species .
    Echinoside A
  • HY-181152
    FGFR3-IN-11

    		FGFR Cancer
    FGFR3-IN-11(compound B11) is a Fibroblast growth factor receptor 3 (FGFR3) inhibitor with a Ka value of 4.8 μM. FGFR3-IN-11 induces apoptosis, suppresses colony formation, and causes dose-dependent G0/G1 cell cycle arrest in cancer cells. FGFR3-IN-11 exerts anticancer activity against cancer cells with minimal toxicity toward normal hepatocytes and demonstrates tumor growth suppression in xenograft mouse models. FGFR3-IN-11 can be used for the research of hepatocellular carcinoma .
    FGFR3-IN-11
  • HY-181054
    Mcl-1-IN-21

    		Bcl-2 Family Apoptosis Reactive Oxygen Species (ROS) Cancer
    Mcl-1-IN-21 is a selective Mcl-1 protein inhibitor. Mcl-1-IN-21 can induce apoptosis, elevate intracellular ROS, reduce mitochondrial membrane potential, exert cytotoxicity against human cervical cancer cells, and inhibit tumor growth in a human cervical cancer xenograft mouse model. Mcl-1-IN-21 can be used for the research of cervical cancer .
    Mcl-1-IN-21
  • HY-181491
    Tubulin-IN-64

    		Microtubule/Tubulin EGFR Akt mTOR Ras Apoptosis Autophagy Cancer
    Tubulin-IN-64 is a sulfonated styrylquinazoline derivative with high selectivity antitumor activity. Tubulin-IN-64 targets tubulin, inhibits the EGFR/Akt/mTOR and EGFR/Ras signaling pathways, induces cell cycle arrest, apoptosis and autophagy. Tubulin-IN-64 exhibits significant antitumor efficacy in the zebrafish GBM xenograft model. Tubulin-IN-64 can be used for the research on glioblastoma and leukemia .
    Tubulin-IN-64
  • HY-181529
    NCATS-SM0225

    		VDAC PERK Cancer
    NCATS-SM0225 is an endoplasmic reticulum-associated degradation (ERAD) inhibitor and a direct binder of VDAC1, VDAC2 and VDAC3. NCATS-SM0225 exhibits an IC50of 1.02 μM for ERAD and a Kd of 3.13 μM for human VDAC1 binding. NCATS-SM0225 disrupts cellular calcium homeostasis, enhances VDAC1-IP3R coupling and activating PERK. NCATS-SM0225 selectively kills cancer cells, exhibits tumor growth inhibitory effects in melanoma xenograft models. NCATS-SM0225 can be used for research on multiple cancers including melanoma, as well as the molecular mechanisms of ERAD and calcium homeostasis regulation .
    NCATS-SM0225

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: